Broncovaleas ® - Salbutamol
Broncovaleas ® is a drug based on Salbutamol sulphate
THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive respiratory tract syndromes
Indications Broncovaleas ® - Salbutamol
Broncovaleas ® is indicated in the treatment of bronchial asthma and obstructive bronchopathy with asthmatic component.
Mechanism of action Broncovaleas ® - Salbutamol
Salbutamol, the active ingredient of Broncovaleas ®, is a sympathomimetic amine belonging to the category of selective beta 2 adrenergic receptor agonists, characterized by an estimated half-life between 2 and 7 hours.
The main mechanism of action of the aforesaid active principle is carried out through the binding and activation of the Beta 2 adrenergic receptors expressed by the tracheo-bronchial musculature, with a consequent increase in cyclic AMP and relative bronchodilation.
This seems to be supported also by other mechanisms of action, not yet fully understood, which associate Salbutamol with a potential stabilizing action on the mast cell membrane, effective in reducing the phenomenon of degranulation and release of vasoactive amines responsible for the classic allergic and asthmatic symptoms.
The portion of drug eventually absorbed is generally excreted via the urine in part unchanged and in part conjugated to glucuronic acid.
Studies carried out and clinical efficacy
SALBUTAMOL AS A PREDICTOR OF ASTHMATIC ATTACKS
Clin Exp Allergy. 2013 Oct; 43: 1144-51. doi: 10.1111 / cea.12166.
Metrics of salbutamol use as predictors of future adverse outcomes in asthma.
Patel M, Pilcher J, Reddel HK, Pritchard A, Corin A, Helm C, Tofield C, Shaw D, Black P, Weatherall M, Beasley R; SMART Study Group.
Interesting study that associates the risk of developing worsening of the asthmatic picture with the frequency of salbutamol consumption, thus being able to use this value as a predictor of the risk of severe asthmatic attacks.
SALBUTAMOL AND HYPRATROPIO BROMIDE IN COMPARISON
Eur J Clin Pharmacol. 2012 Oct; 68: 1375-83. doi: 10.1007 / s00228-012-1256-z. Epub 2012 Mar 29.
Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma.
Dahlén B, Gómez FP, Casas A, Howarth PH, Dahlén SE, Rodriguez-Roisin R.
Study that demonstrates how salbutamol is better than other drugs used for the treatment of asthma such as Ipratropium bromide in preventing spirometric changes related to gas exchange, probably associated with the improvement of other parameters such as the presence of exudate in the respiratory tract.
SALBUTAMOL IN PEDIATRICS
Br J Nurs. 2012 Apr 26-May 9; 21: S30-4.
An algorithm for the use of intravenous salbutamol in children.
Clayton S, Gilchrist F, Alexander J, Enberby B, Lenney W.
Important revision, which seeks to standardize the therapy with salbutamol, identifying a useful algorithm in the intravenous administration of salbutamol in children, so that everything can be achieved in the safest possible way.
Method of use and dosage
Pressurized suspension for inhalation of 100 mcg of Salbutamol per delivery;
0.5% salbutamol solution to be nebulized;
2 mg syrup of Salbutamol per 5 ml of product.
The choice of the pharmaceutical format, the dosage to be used and the timing of intake is up to the doctor after having carefully assessed the patient's overall health status and the severity of his clinical picture.
Generally in adults it is recommended to use 2 sprays 3-6 times a day, 5 drops to be sprayed in 2 ml of distilled water 3 times a day or 2-4 ml of syrup twice a day.
Broncovaleas ® warnings - Salbutamol
Therapy with Broncovaleas ® must necessarily be preceded by a careful medical examination aimed at clarifying the clinical origin of the symptoms and the possible prescribing appropriateness of Salbutamol.
therapy with this drug should take place with particular caution in patients suffering from cardiovascular pathologies, glaucoma, hyperthyroidism, pheochromocytoma, diabetes and prostatic hypertrophy, definitely more exposed to an aggravation of the clinical picture present.
Medical supervision during the entire treatment is necessary in order to ascertain the therapeutic efficacy and safety of the same.
Broncovaleas ® contains among its excipients parahydroxybenzoates, potentially responsible for allergic reactions, including bronchospasm, and sucrose, generally contraindicated in patients with hereditary fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase enzyme deficiency.
The use of Broncovaleas ®, outside the medical prescriptions for which it is indicated, is prohibited in and out of the competition.
It is recommended to store the drug out of the reach of children.
PREGNANCY AND BREASTFEEDING
The use of Broncovaleas ® during pregnancy and in the subsequent lactation period is generally not recommended during pregnancy and in the subsequent period of breastfeeding, due to the muscle relaxant action on uterine muscles, and for the ability of Salbutamol to concentrate in breast milk. .
Patients treated with Broncovaleas ® should avoid the simultaneous intake of beta 2 agonist drugs and non-selective beta blockers, as well as diuretics, steroids and xanthine derivatives, potentially responsible for hypokalaemia.
Contraindications Broncovaleas ® - Salbutamol
The use of Broncovaleas ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients with severe heart disease, glaucoma, prostatic hypertrophy and urinary retention or intestinal obstruction syndrome:
Undesirable Effects - Side Effects
Broncovaleas ® therapy may expose the patient to the risk of hypokalaemia, nervousness and restlessness, dizziness, headache and tremor, myalgia, muscle spasm, arrhythmia, palpitations and tachycardia. Inhalation use could also lead to throat irritation, dry mouth and paradoxical bronchospasm.
The onset of symptoms linked to hypersensitivity to the active ingredient has also rarely been documented.
Broncovaleas ® is a prescription drug.
The information on Broncovaleas ® - Salbutamol published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.